Fig. 1 | npj Breast Cancer

Fig. 1

From: Clinical relevance of the 21-gene Recurrence Score® assay in treatment decisions for patients with node-positive breast cancer in the genomic era

Fig. 1

Recurrence Score distribution among studies in this analysis of the Recurrence Score assay in node-positive breast cancer (N = 9055). aThe WSG PlanB study enrolled patients with pN0 and pN1-3 breast cancer, but this analysis includes only those with 1–3N+; RS cut-points used were non-standard: RS <12, RS 12–25, and RS ≥26

Back to article page